GIP activation plays a critical role in improving how cells respond to insulin
Moreover, the recent proactive focus on weight-loss maintenance (seen in the ongoing Phase 1 maintenance trial) shows VK2735 as not just as another entrant in obesity, but as a complete program with credible differentiation across magnitude, speed, metabolic breadth, and long-term strategy
Likewise, tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, has outperformed many comparators in clinical trials, offering additional benefits like improved lipid profiles
1 (download XLSX Numerical data
Understanding likely future developments helps inform long-term decisions about peptide use
You may be eating less food but you still need the nutrients that keep you strong and prevent you from getting sick